2022
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCohort StudiesCOVID-19COVID-19 TestingEmtricitabineHIV InfectionsHumansLamivudineMaleSARS-CoV-2TenofovirConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regression
2020
Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer
Hysell K, Yusuf R, Barakat L, Virata M, Gan G, Deng Y, Perez-Irizarry J, Vega T, Goldberg SB, Emu B. Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer. Clinical Lung Cancer 2020, 22: e498-e505. PMID: 33468393, PMCID: PMC8169710, DOI: 10.1016/j.cllc.2020.11.006.Peer-Reviewed Original ResearchConceptsCell lung cancerGeneral patientsNSCLC populationLung cancerCox proportional hazards modelYale-New Haven HospitalGeneral NSCLC populationOutcomes of patientsOverall median survivalRetrospective cohort studyPredictors of survivalKaplan-Meier curvesHIV-1 RNACopies/mLLog-rank testProportional hazards modelNew Haven HospitalCancer treatment regimensMedian CD4Antiretroviral therapyCohort studyMedian survivalOverall survivalHIV infectionMedian ageSubstantial gap in primary care: older adults with HIV presenting late to care
Yasin F, Rizk C, Taylor B, Barakat LA. Substantial gap in primary care: older adults with HIV presenting late to care. BMC Geriatrics 2020, 20: 438. PMID: 33129258, PMCID: PMC7603686, DOI: 10.1186/s12877-020-01842-y.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-HIV AgentsHIV InfectionsHumansPrimary Health CareRetrospective StudiesViral LoadConceptsHuman immunodeficiency virusCombination antiretroviral therapyViral suppressionCART initiationHIV clinicOlder patientsRetrospective medical record reviewHIV viral suppressionMedical record reviewPatient demographic dataSerious public health concernPublic health concernAntiretroviral therapyCD4 countHIV testingRecord reviewImmunodeficiency virusPrimary careOlder adult groupTreatment strategiesNew diagnosisAdvanced stagePatientsDemographic dataAdult group
2019
Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals
Sopeyin A, Zhou L, Li M, Barakat L, Paintsil E. Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals. PLOS ONE 2019, 14: e0226573. PMID: 31846498, PMCID: PMC6917281, DOI: 10.1371/journal.pone.0226573.Peer-Reviewed Original ResearchConceptsTreatment-experienced individualsAntiretroviral therapyCholesterol biosynthesis genesSide effectsEffect of ARTLow density lipoprotein receptor pathwayHIV viral suppressionCase-control studyLipoprotein receptor pathwaySterol regulatory element-binding protein 2Cassette transporter A1Protein expression levelsViral suppressionLipid abnormalitiesClinical manifestationsMetabolic derangementsCardiovascular diseaseRetrospective analysisTherapeutic benefitProtein 2 geneMRNA expressionReceptor pathwayMarked decreaseDysregulationExpression levels
2018
Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings
Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2018, 23: 190-200. PMID: 30145707, PMCID: PMC7020905, DOI: 10.1007/s10461-018-2260-9.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useUnhealthy alcoholPre-exposure prophylaxisUnhealthy substance useDrug useHIV acquisitionAlcohol useSubstance useHIV pre-exposure prophylaxisReal-world clinical settingProspective observational studyHIV-positive partnerHIV risk behaviorsStructured clinical assessmentFrequent drug usePrEP outcomesPrEP useRisk factorsClinical assessmentObservational studyPositive partnerReal-world settingMultivariate analysisYounger ageSexual partners
2016
Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study
Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedViral LoadViremiaConceptsVirologic failureViral load levelsPill burdenAlcohol useHuman immunodeficiency virus (HIV) careLow-level HIV viremiaUndetectable viral load levelsAntiretroviral regimen changesAntiretroviral therapy changesExperienced virologic failureLow-level viremiaIntravenous drug useSubset of patientsFrequent clinic visitsPoor clinical outcomePossible risk factorsHepatitis C virusHIV viremiaMore comorbiditiesNonfailure groupVirologic suppressionVirological failureCD4 countConsecutive chartsClinic visits
2014
Antiretroviral Therapy–Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase‐γ Inhibition
Selvaraj S, Ghebremichael M, Li M, Foli Y, Langs-Barlow A, Ogbuagu A, Barakat L, Tubridy E, Edifor R, Lam W, Cheng Y, Paintsil E. Antiretroviral Therapy–Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase‐γ Inhibition. Clinical Pharmacology & Therapeutics 2014, 96: 110-120. PMID: 24637942, PMCID: PMC4065195, DOI: 10.1038/clpt.2014.64.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsATP-Binding Cassette TransportersCase-Control StudiesDeoxyribonucleotidesDNA Polymerase gammaDNA-Directed DNA PolymeraseDNA, MitochondrialFemaleGene DosageHIV InfectionsHumansMaleMiddle AgedMitochondriaNucleic Acid Synthesis InhibitorsNucleotide Transport ProteinsNucleotidesReverse Transcriptase InhibitorsRibonucleotidesConceptsAntiretroviral therapyPeripheral blood mononuclear cellsMitochondrial toxicityBlood mononuclear cellsNegative controlMitochondrial DNA copy numberMononuclear cellsDNA copy numberMitochondrial dysfunctionHigh expression levelsPotential mechanismsGroup differencesExpression levelsPositive controlTherapyMedian valueToxicityDeoxyribonucleotide poolsCellular kinasesCassette proteinCellsDysfunctionTriphosphateControl